April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Clinical Potential of onCARlytics Under Exploration in Solid Tumors
August 4th 2021Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s potential in this patient population.
Read More
Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL
July 8th 2021Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.
Watch
Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma
June 16th 2021Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.
Read More
Axi-Cel Outperforms Alternate Treatments in R/R Follicular Lymphoma
June 14th 2021Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Read More
CAR T Therapy Effective for Numerous Hematologic Malignancies, Even in Heavily Pretreat Patients
May 27th 2021In an interview with Targeted Oncology, Deepu Madduri, MD discussed the need for further CAR T-cell therapy research, expanding it into other hematology malignancies. She also discussd management of the common adverse events associated with CAR T cells.
Read More
FDA Grants Fast Track Designation to Novel CAR T-Cell Therapy for Thyroid Cancers
May 19th 2021The FDA has granted a fast track designation to the autologous chimeric antigen receptor T-cell agent, AIC100, for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
Read More
Safety/Feasibility of CAR T-Cell Therapy Being Investigated in Brain Tumors
May 18th 2021The first patient has been dosed in a study designed to evaluate the safety and feasibility of IL13Rα2 chimeric antigen receptor T cell therapy for the treatment of leptomeningeal brain tumors, such as glioblastoma, ependymoma, and medulloblastoma.
Read More
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World Settings
May 15th 2021Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Read More
Liso-Cel Efficacy Not Impacted by Prior CD19 Exposure in LBCL
April 25th 2021In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.
Read More
When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
Immune System Plays Important Role in CAR T Cell Responses in Glioblastoma Models
April 16th 2021Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.
Read More
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL
April 12th 2021Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
Watch
Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel
March 24th 2021In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.
Read More
Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCL
March 24th 2021Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.
Read More
Exploring the Potential of PSCA-Targeted CAR T-Cell Therapy to Treat mCRPC
March 23rd 2021Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.
Read More
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond
March 6th 2021The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Read More